West Pharmaceutical Services, Inc. (WST): A Bull Case Theory

We came across a bullish thesis on West Pharmaceutical Services, Inc. (WST) on Swiss Transparent Portfolio’s Substack. In this article, we will summarize the bulls’ thesis on WST. West Pharmaceutical Services, Inc. (WST)’s share was trading at $208.49 as of 22^nd May. WST’s trailing and forward P/E were 32.73 and 34.36respectively according to Yahoo Finance.

West Pharmaceutical Services stands out as a durable, underappreciated leader in the critical niche of injectable drug packaging. Despite recent headwinds from a post-Covid inventory glut and short-term earnings softness, the company’s fundamentals remain strong. West holds a near-monopoly in a mission-critical industry with high switching costs, secular growth drivers like biologics and GLP-1 therapies, and a conservative, high-quality management team. Its financial turbulence appears transient, offering long-term investors an opportunity to accumulate shares at a fair price.

While the current ~32x forward P/E may appear elevated, it’s based on temporarily depressed earnings; normalized multiples suggest a more reasonable valuation. West’s strategic investments during the downturn — including capacity expansion and share repurchases — reinforce its long-term potential. Risks such as customer concentration, technological disruption, execution missteps, regulatory issues, and macroeconomic volatility are real but manageable. The company’s embedded role in drug delivery makes sudden disruptions unlikely, and its century-long record of quality execution offers confidence.

Scenario analysis shows a compelling risk/reward balance: the bull case projects a ~15% CAGR, while even the bear case requires a confluence of major setbacks to yield sustained losses. West is not a flashy growth story but rather a compounder built on operational excellence, customer entrenchment, and resilient demand. For investors comfortable with a mid-30s P/E as a reflection of quality, West offers a rare blend of safety and growth. It’s a Rolls-Royce business at a Bentley price — a quiet engine of compounding that, barring major failure, should keep running reliably for years to come.

West Pharmaceutical Services, Inc. (WST) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 35 hedge fund portfolios held WST at the end of the fourth quarter which was 31 in the previous quarter. While we acknowledge the risk and potential of WST as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than WST but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.

Disclosure: None. This article was originally published at Insider Monkey.